AVTX - Company ID 0001534120
The table below shows Avalo Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $59.00K | $441.00K | $1.92M | $18.05M | $5.40M | $6.70M |
| Cost of revenue | - | - | $1.28M | $3.43M | $1.49M | $300.00K |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Avalo Therapeutics, Inc. reported annual revenue of $59.00K for fiscal year 2025. That is down 86.6% from $441.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $1.15M (FY 2016) to $59.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $22.90M |
| $17.24M |
| $10.30M |
| $20.71M |
| $24.66M |
| $17.42M |
| Operating income | -$72.92M | -$68.51M | -$27.35M | -$37.44M | -$82.13M | -$72.84M |
| Income tax | $165.00K | $114.00K | $14.00K | $28.00K | -$196.00K | -$2.79M |
| Net income | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -$84.38M | -$63.50M |
| EPS (diluted) | -$5.84 | -$20.91 | -$113.58 | -$1.06K | - | - |